Please login to the form below

Not currently logged in
Email:
Password:

CLL

This page shows the latest CLL news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

who are ineligible for intensive chemotherapy, to goalong with its existing indications in chronic lymphocytic leukaemia (CLL).

Latest news

  • Roche and AbbVie prepare to move Venclexta into first-line CLL Roche and AbbVie prepare to move Venclexta into first-line CLL

    the pairing as a first-line CLL regimen that spares patients from having to undergo chemotherapy. ... It was the first chemotherapy-free option for patients, having topped chlorambucil in trials, and is credited with re-shaping the CLL market.

  • Roche keeps Venclexta train rolling with new leukaemia filing Roche keeps Venclexta train rolling with new leukaemia filing

    Venclexta was first approved as a second-line therapy for chronic lymphocytic leukaemia (CLL) patients with a chromosomal abnormality known as 17p deletion in 2016 and – last month – the eligible patient ... population was expanded after the

  • AbbVie, Roche get FDA OK for broader use of Venclexta AbbVie, Roche get FDA OK for broader use of Venclexta

    A regimen based on AbbVie/Roche’s Venclexta for chronic lymphocytic leukaemia (CLL) - which has been described as ‘practice-changing’ - has been approved in the US. ... It means that the chemotherapy-free regimen can be used in a much broader

  • AbbVie trial backs chemo-free Imbruvica combo regimen AbbVie trial backs chemo-free Imbruvica combo regimen

    trial – raising the prospect of a new chemotherapy-free combination regimen for previously untreated CLL patients. ... or more) with either CLL or small lymphocytic leukaemia (SLL) – a different form of the same disease.

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    The first BTK inhibitor to reach the market was Johnson &Johnson (J&J) and Pharmacyclics' Imbruvica (ibrutinib), but this has been introduced initially for blood cancers including chronic lymphocytic leukaemia (CLL)

More from news
Approximately 11 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Asset acquisition - products. 121. †Eagle Pharmaceuticals/ Teva. EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL. ... CLL, chronic lymphocytic leukaemia;  NHL, indolent non-Hodgkin lymphoma.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3). ... Abbreviations. ImmTacs = Immune mobilising mTCR against cancer. CLL = chronic lymphocytic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics